Clinical Trial

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2023 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
Trial Details
NCT Number NCT05775705
Lead Sponsor Beijing Friendship Hospital
Conditions PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Lymphoma
Enrollment 25 participants
Start Date 2023-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2023-03-20